Ciprofloxacin Lactate for Injection

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often also has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

The content of ciprofloxacin lactate should be calculated as ciprofloxacin (C17H18FN3O3), which should be 90.0% to 110.0% of the labeled amount

Applicable to infections caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal tract infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, hydrophilic monocytic bacteria, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Systemic infections such as sepsis.

Before use, dissolve it in 200ml 5% glucose injection or 200ml sodium chloride injection. The usual dose for adults is 0.2g per day, intravenously dripped once every 12 hours, and the drip time is not less than 30 minutes. For severe infection or Pseudomonas aeruginosa infection, the dose can be increased to 0.8g per day, intravenously dripped twice. Course of treatment: 1. Urinary tract infection: 5 to 7 days for acute simple lower urinary tract infection; 7 to 14 days for complicated urinary tract infection. 2. Pneumonia and skin and soft tissue infection: 7 to 14 days. 3. Intestinal infection: 5 to 7 days. 4. Bone and joint infection: 4 to 6 weeks or longer. 5. Typhoid fever: 10 to 14 days.

1. Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, skin itching, occasionally exudative erythema multiforme and angioneurotic edema. A small number of patients have photosensitivity reactions. 4. Occasionally, the following may occur: 1. Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. 2. Manifestations of interstitial nephritis such as hematuria, fever, and rash. 3. Phlebitis. 4. Crystalluria, more common when used in high doses. 5. Joint pain. 5. A small number of patients may experience elevated serum aminotransferases, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

1. Urine alkalinizers can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When this product is used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the hepatic clearance of theophylline, a prolonged blood elimination half-life (t1/2()), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Therefore, the blood drug concentration of theophylline should be measured and the dose adjusted when used in combination. 3. Cyclosporine and this product can increase the blood drug concentration of the former. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter. When used in combination, the patient's prothrombin time should be closely monitored. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may produce toxicity due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, resulting in a decrease in caffeine clearance, a prolonged blood elimination half-life (t1/2()), and possible central nervous system toxicity.

Keep away from light and store in a sealed container.

0.1g (as ciprofloxacin)

Eisai Liaoning Pharmaciutical Co., Ltd.

• Founded in:

  2011-12-19

• Address:

  No. 39, Pingtai 2nd Street, Benxi Economic and Technological Development Zone

• Tax NO.:

  912105005873118435

• Registered Funds:

  50 million yuan

• Email:

  Log in to view